Phibro Animal Health (PAHC) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UroGen Pharma (URGN) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 6.9% versus a loss of 20.0%. Over five years, URGN leads with a +127.8% price change compared with +59.4% for PAHC. UroGen Pharma is the larger company by market cap ($1.36 billion vs $1.35 billion), about 1.0 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (8.6x vs 11.1x for UroGen Pharma). Phibro Animal Health pays a dividend yielding 1.44%, while UroGen Pharma does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | URGN |
|---|---|---|
| Share price | $33.29 | $27.65 |
| Market cap | $1.35B | $1.36B |
| 1-day change | -2.32% | -12.86% |
| YTD return | -10.89% | +18.06% |
| 1-year return | -20.03% | +6.88% |
| 5-year return | +59.43% | +127.76% |
| P/E ratio (TTM) | 13.26 | — |
| Forward P/E | 8.58 | 11.08 |
| EPS (TTM) | $2.51 | $-1.31 |
| Dividend yield | 1.44% | 0.00% |
| Annual dividend | $0.48 | $0.00 |
| Revenue (latest FY) | $1.52B | $109.79M |
| Revenue growth (YoY) | +17.12% | +21.45% |
| Net income (latest FY) | $99.72M | $-153.49M |
| Gross margin | 33.76% | 88.66% |
| Operating margin | 12.81% | -113.73% |
| Net margin | 6.57% | -139.81% |
| 52-week high | $60.08 | $50.81 |
| 52-week low | $28.25 | $16.50 |
| Distance from 52-week high | -44.59% | -45.58% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +41.18% | +119.57% |
| Average volume | 228.99K | 1.11M |
| Shares outstanding | 21.11M | 49.05M |
| Employees | 2,605 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed PAHC by 26.9 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.44% vs 0.00%).
- Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
PAHC vs URGN FAQ
Which is bigger, Phibro Animal Health or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.36B compared with $1.35B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, PAHC or URGN?
URGN returned +6.88% over the past 12 months, compared with -20.03% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Phibro Animal Health or UroGen Pharma?
Phibro Animal Health pays a dividend yielding 1.44%, while UroGen Pharma does not currently pay a regular dividend.
Are Phibro Animal Health and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.